A simple, precise, isocratic, reverse-phase high-performance liquid chromatography method was developed for the rapid determination of arteether using an Agilent RP C 18 , 4.6 3 150 mm, 5 mm XDB column. The runtime was 9 min. The effect of flow rate, injection volume and mobile phase composition on resolution was investigated. The analytical procedures of the method were validated with respect to precision, accuracy and linearity according to the International Conference on Harmonization guidelines. The limit of detection and the limit of quantitation were 3.3 and 10.0 mg/mL, respectively. Linearity range was from 10.00 to 500 mg/mL. Further, the proposed method was found to be reproducible and convenient for stability-indicating analysis of arteether as a bulk drug and from nanoparticulate formulation.
Introduction
Arteether (b-dihydroartemisinin ethylether) was recently introduced as a novel semi-synthetic highly potent antimalarial drug ( Figure 1a ). Its antimalarial activity depends on its internal peroxide linkage. In contrast to many other antimalarials, arteether does not contain a nitrogen-containing heterocycle ring system. Arteether has been reported to be excellent in parasite clearance, fever disappearance and early recovery and has no serious side effects. The drug is also crystalline, has good storage stability and is a highly lipophilic compound, ideally suited for intramuscular injection (1) . It was found to have a remarkable curative effect against the erythrocytic stage of chloroquine-and mefloquine-resistant strains of Plasmodium falciparum. Arteether has been selected as drug of choice for evaluating treatment efficacy in patients suffering from cerebral malaria (2) . As arteether has a very low water solubility (17 mg/mL), it is unsuitable for intravenous or oral administration. Oral administration of arteether is expected to show low bioavailability due to slow drug dissolution as well as drug decomposition by stomach acid and hepatic metabolism (3) .
There are many reported methods for the determination of arteether in pharmaceutical dosage forms and biological fluids, namely high-performance liquid chromatography (HPLC) (4, 5) , liquid chromatography tandem mass spectrometry (6 -8) , HPLC with reductive electrochemical detection (9) , thermospray HPLC/mass spectrometry (10), liquid chromatographic/electrospray ionization tandem mass spectrometry (11) and HPLC-MS-MS (12) . None of the reported analytical methods describe a stability-indicating method for the determination of arteether. To our knowledge, this is the first report of a stability-indicating method for the determination of arteether as plain drug and in poly-lactic-co-glycolic acid (PLGA) nanoparticles. Thus, the aim of the present work was to develop an accurate, specific, reproducible and stability-indicating HPLC method for the determination of arteether, degradation products and related impurities from a pharmaceutical dosage form, namely nanoparticles.
Experimental

Materials and reagents
Arteether was a generous gift sample from Ipca Pharmaceuticals Pvt Ltd., Mumbai, India. HPLC-grade acetonitrile and methanol were purchased from SD Fine Chemicals (Mumbai, India). 0.45 mm membranes were purchased from Pall Life Sciences. All other chemicals used were of analytical grade unless otherwise indicated. Highly pure water obtained from a Milli Q Plus purification system (Millipore, Bedford, MA, USA) was used for the preparation of mobile phase.
Instrumentation
The HPLC system consisted of a Plus Intelligent LC pump PU-2080 from Jasco (Tokyo, Japan) equipped with a Jasco UV-2075 Intelligent UV-Vis detector and a Rheodyne 7725 injector (Rheodyne, Cotati, CA, USA). The output signal was monitored and processed using a Jasco Chroma Pass Chromatography Data System Software (Version 1.8.6.1). Chromatographic separation was achieved on a 5-mm Agilent RP C 18 Zorbax eclipse XDB column (4.6 Â 150 mm). The mobile phase employed comprised Solvent A:Water and Solvent B:Acetonitrile. Prior to use, water was filtered through a 0.45-mm filter membrane. Mobile phase was pumped through the column at a flow rate of 1.0 mL/min. The injection volume was 50 mL. The analytes were analyzed at a single wavelength of 216 nm for arteether and their associated degradation products.
Preparation of stock and standard solutions A stock solution of arteether (5 mg/mL) was prepared by dissolving accurately weighed 250 mg arteether in methanol using a 50 mL volumetric flask. Standard solutions were prepared by dilution of the diluted stock solution with methanol to give solutions containing arteether in the concentration range 10-500 mg/mL.
Forced degradation of arteether
The working solutions for the following studies were prepared by subjecting 1 mL of stock solution (5 mg/mL) to various forced degradation conditions to provide an indication of the stabilityindicating property and specificity of the proposed method. Prior to analysis, the resultant solution was diluted with methanol to give solutions containing arteether at a concentration of 500 mg/mL.
Preparation of solutions for acid-and base-induced degradation product To 1 mL of methanolic stock solution of arteether, 1 mL of 0.1 M HCl and 0.1 M NaOH were added separately. These mixtures were heated separately for 1 h at 808C. The forced degradation in acidic and basic media was performed in 10 mL amber volumetric flasks in order to exclude the possible degradative effect of light. The neutralized solutions were injected in triplicate, and chromatograms were run as previously described.
Preparation of hydrogen peroxide-induced degradation product To 1 mL of methanolic stock solution of arteether, 1 mL of hydrogen peroxide (H 2 O 2 , 3%) was added. This solution was heated separately for 1 h at 808C. The forced degradation was performed in 10 mL amber volumetric flask in order to exclude the possible degradative effect of light. The final solution was injected in triplicate and chromatogram was run as previously described.
Photochemical degradation product
One milliliter of methanolic stock solution (5 mg/mL) of arteether was diluted to 10 mL with methanol (500 mg/mL) and the photochemical stability of the drug was studied by exposing the solution to direct sunlight for 1 h.
Heat-induced degradation product
One milliliter of methanolic stock solution of arteether was taken in 10 mL amber volumetric flask and heated for 1 h in water bath maintained at 808C to study the heat degradation. The resultant solution was cooled and injected in triplicate, and the chromatogram was run as previously described. 
Method validation
Accuracy and precision Determination of accuracy and precision was carried out at 10, 100 and 500 mg/mL of arteether concentration. At each level of the amount, six determinations were performed and both intraand interday variations were expressed in terms of % relative standard deviation (% RSD). This was also done to check for the recovery of the drug at different levels in the formulations.
Robustness of the method
By introducing small changes in the mobile-phase composition, injection volume, flow rate and temperature, the effects on the results were examined. In mobile phase, the composition of solvent B was changed by 1%, injection volume was changed from 50 to 20 mL, flow rate was changed by 0.2 units and effect of column temperature was studied at 25, 30 and 358C. For most of the above conditions, the components of the mobile phase were held constant. The robustness of the method was studied in triplicate at a concentration level of 500 mg/mL (13).
Limit of detection and limit of quantification In order to estimate the limit of detection (LOD) and limit of quantitation (LOQ), blank methanol was injected six times following the same method as explained previously. The LOD and LOQ for arteether were estimated at signal-to-noise ratio (S/N) of 3:1 and 10:1, respectively. Precision study was also carried at the LOQ level by injecting six individual preparations of arteether and % RSD was calculated for the areas.
Linearity
Linearity test solutions for arteether were prepared by diluting the stock solution to the required concentrations. The solutions were prepared from LOQ to 500 mg/mL (i.e., LOQ, 25, 50, 100, 250 and 500 mg/mL) and the calibration curves were drawn by plotting the peak areas of arteether against the corresponding concentrations. The slope and the Y-intercept of the calibration curve were calculated.
Solution stability
The solution stability of arteether was performed by leaving a spiked sample (500 mg/mL) solution in a tightly capped volumetric flask at room temperature for 8 h. Content of arteether was determined by following the procedure as previously described.
Analysis of arteether from PLGA nanoparticles
To determine the content of arteether from PLGA nanoparticles, nanoparticles equivalent to 10 mg of arteether (lable claim: 1400 mg of nanoparticles) were accurately weighed and transferred into a 50-mL volumetric flask and volume made up to 50 mL with methanol. To ensure complete extraction of the drug, it was mixed for 2 min. The resulting solution was filtered through a 0.45-mm membrane and injected (200 mg/mL) into the HPLC system, the chromatogram was run as previously described for the drug content analysis. The analysis was repeated in six replicates and the possibility of excipient interference in the analysis was studied.
Results
Development of the optimum mobile phase
The pure drug was injected under both ambient and forced degradation conditions in different solvent systems. Initially, methanol and water were tried in various ratios; however, the chromatogram showed peak splitting of arteether. Hence, methanol was replaced by acetonitrile and acetonitrile:water was used in various ratios: 80:20, 75:25, 70:30. The acetonitrile:-water ratio of 75:25 (v/v) exhibited good peak nature and peaks were found to be symmetrical at 216 nm (Figure 1b) . Tailing factor for peak was ,2% with good resolution. Also, the method was able to separate arteether from its degradation products and related impurities.
The linear regression data for the calibration curves (n ¼ 3) as shown in Table I showed a good linear relationship over the concentration range 10 -500 mg/mL with respect to the peak area.
Stability-indicating property
The chromatograms of the samples treated with acid, base, hydrogen peroxide, heat and photochemical degradation showed well-separated chromatograms of arteether and some degradation peaks at different retention times. The identification of degradants was based on comparison with that of the "standard solution." The chromatograms of the degradation products were well resolved from the arteether peaks (as shown in Figures 1c, d and 2a -c) . The number of degradation products, content of arteether remained and percentage recovery was calculated and are listed in Table II .
Acid-induced degradation product
In addition to the arteether peak, the chromatogram of the aciddegraded sample of arteether showed five additional peaks at 1.3, 1.9, 3.8, 4.2 and 5.3 min (Figure 1c ).
Base-induced degradation product
The chromatogram of the base-degraded sample showed an additional peak at 1.3 and 3.7 min (Figure 1d) . Also, the two main degradation products and several degradation products at low UV intensity are present.
Hydrogen peroxide-induced degradation product
The chromatogram of the sample of arteether treated with 3% (v/v) H 2 O 2 showed an additional peak at 1.3 min (Figure 2a) . 
Photochemical degradation product
The chromatogram of the sample of arteether exposed to photochemical degradation (1 h) showed an additional peak at 1.4 min (Figure 2b ).
Heat degradation product
The samples subjected to heat (at 808C for 1 h) conditions showed an additional peak at 1.3 min (Figure 2c) .
Validation of the method
Accuracy and precision
The accuracy and precision of the method was determined by spiking a known amount of arteether in triplicate at levels low, medium and high of the specified limit (Table III) .
Robustness of the method
The % RSD of the peak areas was calculated for change in mobile-phase composition, injection volume, flow rate, composition of Solvent B was changed by 1% and temperature, at a concentration level of 500 mg/mL in triplicate. (Table IV) .
LOD and LOQ Detection limit and quantification limit were calculated by the method as described previously. S/N of 3:1 and 10:1 were considered LOD and LOQ, respectively, and were found to be 3.33 and 10.0 mg/mL, respectively.
Solution stability % RSD of arteether concentration during solution stability experiments was within 1%. No significant changes were observed for the chromatograms of standard solution and the experimental solution.
Analysis of arteether from PLGA nanoparticles
The arteether content was found to be 101.33% with a % RSD of 0.41. It may, therefore, be inferred that degradation of arteether did not occur in the formulation that was analyzed by this method (Figure 2d ).
Discussion
The HPLC procedure was optimized with a view to developing a stability-indicating assay method to quantify arteether and its degradation products from nanoparticles. The acetonitrile:water ratio of 75:25 (v/v) exhibited good peak nature, and peaks were found to be symmetrical at 216 nm. Tailing factor for peak was ,2% with good resolution. Also, the method was able to separate arteether from its degradation products and related impurities. Extremely significant difference was observed in the slopes of standard curves (analysis of variance, P , 0.0001). After 1 h heating on water bath, the areas of the acid-degraded product peaks were found to be higher than the area of standard arteether concentration (500 mg/mL), indicating that arteether undergoes significant degradation under mild acidic conditions (0.1 N HCl). Drug recovery of acid-degradation product peak was found at a level of 40.19%. The presence of additional degradation peak under mild basic conditions (0.1 M NaOH, 1 h) reconfirmed that the drug undergoes degradation under basic conditions. Recovery at a level of 79.32% suggests susceptibility of arteether to degradation under basic conditions. Drug recovery at a level of 95.67% indicates the degradation of arteether under oxidative conditions. Drug recovery at a level of 95.62% indicates that the drug is unstable toward the photochemical irradiations for the exposure period under study. Drug recovery at a level of 96.84% indicates that the drug is unstable toward heat. The measurement of the peak area showed low values of % RSD ( , 2) for inter-and intraday variation, which suggested an excellent accuracy and precision of the method. The symmetry (,2) and asymmetry (.2) obtained after introducing small deliberate changes in the developed HPLC method indicated the robustness of the method. Further, the absence of degradation peaks confirmed that the sample is stable in solvent used during the assays for 8 h. In the chromatogram of the arteether samples extracted from nanoparticles, there was no interference from the excipients commonly present in formulation. The low % RSD value indicated the suitability of this method for routine analysis of arteether in pharmaceutical dosage forms.
Conclusions
The developed HPLC technique is precise, specific, accurate and stability indicating for the determination of arteether. Statistical analysis also proves that the method is reproducible and specific to the analysis of arteether. The method is versatile in the separate analysis of arteether in bulk drug and in formulation. Finally, the work discussed in this paper provides a unique method capable of separating arteether as well as studying the stability of arteether as a bulk or formulated dosage form, which may include solid oral dosage form and nanoparticles. 
